Xconomy | Boston - Business + Technology in the Exponential Economy

Alnylam’s Ebola Work Gets $7.5 Million Commitment

Alnylam Pharmaceuticals (NASDAQ: ALNY) said today that the National Institutes of Health has committed $7.5 million to continue funding another year of its program to develop RNA interference technology against hemorrhagic fever virus, including the deadly Ebola virus. The Cambridge, MA-based company originally got the contract in September 2006, and has received $14.2 million for work over the first two years. The company’s experimental treatment, which uses a lipid-particle delivery method, has been shown to decrease Ebola virus in infected mice, the company said.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: